M
May Health
A medical device company developing a minimally invasive ablation technology designed to restore ovulation in women with PCOS-related infertility
About May Health
May Health operates in the healthcare sector, focusing on developing innovative treatments for Polycystic Ovary Syndrome (PCOS). The company aims to address the needs of both patients and healthcare professionals by providing a novel solution designed to restore ovulation through targeted ovarian ablation. This one-time treatment aims to lower androgen production, which can often restore ovulation, offering a modern approach to managing PCOS. May Health's business model revolves around extensive research and clinical trials, ensuring their devices meet safety and efficacy standards set by regulatory bodies like the FDA and European Competent Authorities. The company generates revenue through the development and eventual commercialization of its medical devices, targeting a niche but significant market of individuals affected by PCOS. By focusing on both the clinical and informational aspects of PCOS treatment, May Health aims to empower patients and physicians with the knowledge and tools necessary for effective management of the condition.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Paris, France
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 65.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Fertility, Non-Invasive medical devices and treatments, Femtech, Sustainable Development Goals, Tech for Patients, Reproductive Health, biotech medtech and e-health, Observatoire Deeptech
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Latest news
Press, funding announcements and product moves mentioning May Health.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Mar 2026 | $12M | $125M | Bpifrance · Trill Impact · Sofinnova Partners · nexpringhealth.com | ↗ |
| SERIES B✓Equity / VC | May 2024 | $25M | $100M | Sofinnova Partners · Avestria Ventures · Trill Impact · Bpifrance | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for May Health is 1.7K monthly website visits, down 56.4% over the last three months. May Health's team declined 3.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
MedTech Innovator
Series A6 investors entered at this stage
Sofinnova Partners
Sofinnova Investments
Avestria Ventures
Trill Impact
Bpifrance
Kidron
Series B and later1 investor entered at this stage
nexpringhealth.com
Other known investors1 additional known investor
MD Start Accelerator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about May Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See May Health’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.